Arcus Biosciences Inc [RCUS] stock prices are up 3.24% to $15.94 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RCUS shares have gain 8.44% over the last week, with a monthly amount glided 4.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on October 21, 2024, when H.C. Wainwright initiated its Neutral rating and assigned the stock a price target of $20. Previously, Wells Fargo started tracking the stock with Overweight rating on October 08, 2024, and set its price target to $29. On November 18, 2022, BofA Securities initiated with a Neutral rating and assigned a price target of $33 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $40 on October 11, 2022. Berenberg started tracking with a Buy rating for this stock on November 24, 2020, and assigned it a price target of $50. In a note dated November 23, 2020, Evercore ISI initiated an Outperform rating.
The stock price of Arcus Biosciences Inc [RCUS] has been fluctuating between $13.52 and $20.31 over the past year. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $15.94 at the most recent close of the market. An investor can expect a potential return of 107.03% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
The Arcus Biosciences Inc [NYSE:RCUS] reported sales of 263.00M for trailing twelve months, representing a surge of 50.00%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.21%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.46 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.36 points at the first support level, and at 14.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.28, and for the 2nd resistance point, it is at 16.63.
Ratios To Look Out For
It’s worth pointing out that Arcus Biosciences Inc [NYSE:RCUS]’s Current Ratio is 5.23. Also, the Quick Ratio is 5.23, while the Cash Ratio stands at 0.93. Considering the valuation of this stock, the price to sales ratio is 5.42, the price to book ratio is 2.58.
Transactions by insiders
Recent insider trading involved Azoy Alexander, Chief Accounting Officer, that happened on Aug 13 ’24 when 1357.0 shares were sold. Chief Operating Officer, Jarrett Jennifer completed a deal on Mar 27 ’24 to sell 11551.0 shares. Meanwhile, Chief Operating Officer Jarrett Jennifer sold 13449.0 shares on Mar 18 ’24.
